65 patents
Utility
Novel Compounds
7 Dec 23
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
Sreenivasachary Nampally, Emanuele Gabellieri, Veronique Dreyfus Dehlinger
Filed: 11 Oct 21
Utility
Method of Safe Administration of Phosphorylated TAU Peptide Vaccine
30 Nov 23
Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described.
Andrea Pfeifer, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire, Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka
Filed: 12 May 23
Utility
Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates
14 Nov 23
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
Filed: 9 Jan 20
Utility
Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
26 Oct 23
Methods for inducing a sustained immune response against phosphorylated Tau in humans are described.
Andrea Pfeifer, Andreas Muhs, Wendy Galpern
Filed: 28 Jun 23
Utility
Misfolded TDP-43 Binding Molecules
26 Oct 23
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43).
Tamara Seredenina, Oskar Adolfsson
Filed: 7 Oct 22
Utility
Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
12 Oct 23
The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43).
Tamara Seredenina, Tamar Magdalena Ziehm, Tariq Afroz, Romain Christian Ollier
Filed: 13 Aug 21
Utility
Immunogenic Compounds
14 Sep 23
An antigenic peptide comprises the structure X1-X2-X3-X4-X5-X6-X7-P-X9-X10-X11-X12 and is derived from amino acids 113-124 of alpha synuclein.
Dorian Winter, Günther Staffler, Gergana Galabova, Eva Mihailovska, Petra Gruber, Katja Balazs
Filed: 4 Aug 21
Utility
Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates
17 Aug 23
The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).
Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
Filed: 4 Apr 23
Utility
Heterologous Administration of Tau Vaccines
17 Aug 23
Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described.
Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
Filed: 20 Feb 23
Utility
Dihydrooxazole and Thiourea Derivatives Modulating the NLRP3 Inflammasome Pathway
10 Aug 23
The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of the NLRP3 inflammasome pathway.
Emanuele GABELLIERI, Jérôme MOLETTE, Véronique DEHLINGER
Filed: 18 Jun 21
Utility
Mimotopes of Alpha-synuclein and Vaccines Thereof for the Treatment of Synucleinopathy
29 Jun 23
Markus MANDLER, Harald WENINGER, Radmila SANTIC, Edith KOPINITS
Filed: 21 Nov 22
Utility
Method of safe administration of phosphorylated tau peptide vaccine
27 Jun 23
Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described.
Andrea Pfeifer, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire, Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka
Filed: 7 Feb 20
Utility
Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates
27 Jun 23
Sreenivasachary Nampally, Emanuele Gabellieri, Jerome Molette
Filed: 30 May 19
Utility
Dose Treatments of Tauopathies
20 Apr 23
The present invention relates to the use of ACI-3024 in the treatment, alleviation or prevention in humans of a group of disorders and abnormalities associated with Tau protein aggregates, such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP).
Sonia Maria Poli, Francesca Capotosti
Filed: 18 Mar 21
Utility
Bicyclic compounds for diagnosis and therapy
11 Apr 23
The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synuclein (α-synuclein, A-synuclein, aSynuclein, A-syn, α-syn, aSyn) aggregates including, but not limited to, Lewy bodies and/or Lewy neurites, such as Parkinson's disease.
Jérôme Molette, Emanuele Gabellieri, Vincent Darmency
Filed: 5 Jun 20
Utility
Heterologous administration of tau vaccines
28 Feb 23
Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described.
Elizabeth Anne Ramsburg, Donata De Marco, Chakkumkal Anish, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
Filed: 23 Apr 20
Utility
Anti-tau Antibodies and Methods of Use
9 Feb 23
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Isidro Hotzel, Danielle DiCara
Filed: 22 Jun 22
Utility
Novel Molecules for Diagnosis
2 Feb 23
The present invention relates to novel amyloid-beta (abeta) binding molecules, in particular to abeta antibodies or antigen-binding fragments thereof and/or uses thereof.
Oskar Mario Adolfsson, Katarzyna Ewa Piorkowska
Filed: 10 Sep 20
Utility
Anti-Tau antibodies and methods of use
17 Jan 23
The invention provides anti-Tau antibodies and methods of using the same.
Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
Filed: 3 Dec 20
Utility
Mimotopes of alpha-synuclein and vaccines thereof for the treatment of synucleinopathy
27 Dec 22
A method of treating a synucleinopathy with a peptide (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), (C)DSPVLPD (SEQ ID NO: 61), (C)DQPVLPDN (SEQ ID NO: 64), (C)DMPVLPDN (SEQ ID NO: 65), (C)DSPVLPDN (SEQ ID NO: 66), (C)HDRPVTPD (SEQ ID NO: 70), (C)DRPVTPD (SEQ ID NO: 71), (C)DVPVLPD (SEQ ID NO: 72), (C)DTPVYPD (SEQ ID NO: 73), (C)DTPVIPD (SEQ ID NO: 74), (C)HDRPVTPDN (SEQ ID NO: 75), (C)DRPVTPDN (SEQ ID NO: 76), (C)DVPVLPDN (SEQ ID NO: 78), (C)DTPVYPDN (SEQ ID NO: 79), (C)DQPVLPDG (SEQ ID NO: 81), (C)DMPVLPDG (SEQ ID NO: 82), (C)DSPVLPDG (SEQ ID NO: 83), (C)DHPVHPDS (SEQ ID NO: 86), (C)DMPVSPDR (SEQ ID NO: 87), (C)DRPVYPDI (SEQ ID NO: 90), (C)DHPVTPDR (SEQ ID NO: 91), (C)DTPVLPDS (SEQ ID NO: 93), (C)DMPVTPDT (SEQ ID NO: 94), (C)DAPVTPDT (SEQ ID NO: 95), (C)DSPVVPDN (SEQ ID NO: 96), (C)DLPVTPDR (SEQ ID NO: 97), (C)DSPVHPDT (SEQ ID NO: 98), (C)DAPVRPDS (SEQ ID NO: 99), (C)DMPVWPDG (SEQ ID NO: 100), (C)DRPVQPDR (SEQ ID NO: 102), (C)YDRPVQPDR (SEQ ID NO: 103), (C)DMPVDADN (SEQ ID NO: 105), DQPVLPD(C) (SEQ ID NO: 106), and DMPVLPD(C) (SEQ ID NO: 107.
Markus Mandler, Harald Weninger, Radmila Santic, Edith Kopinits
Filed: 11 Dec 19